Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Pfizer Reports Results From Two Lyrica Capsules CV Phase 3b Studies
NASDAQ.com
Friday, October 18, 2013 - 11:03am
tags:
Pfizer, Lyrica, fibromyalgia, diabetic neuropathy
Switzerland Seizes One Million Fake Pfizer Pills in Zurich Airport
Bloomberg
Friday, October 18, 2013 - 11:00am
tags:
drug counterfeiting, Pfizer, Xanax, Switzerland
Upcoming Catalysts Should Provide Strong Upside For These BioPharma Companies
Seeking Alpha
Friday, October 18, 2013 - 10:51am
tags:
Celldex, ImmunoCellular Therapeutics, Enanta, Merrimack Pharmaceuticals, Vanda
Johnson & Johnson Continues To Ride The Success Of Its Immunology And Oncology Drugs
Seeking Alpha
Friday, October 18, 2013 - 10:07am
tags:
JNJ, Remicade, Simponi, Stelara, Invokana
AstraZeneca hit with lawsuit by former employee
West Virginia Record
Friday, October 18, 2013 - 9:54am
tags:
AstraZeneca, sexual harassment
Alimera, pSivida Eye Drug Rejected by FDA
TheStreet.com
Friday, October 18, 2013 - 9:52am
tags:
Alimera, pSivida, FDA, Iluvien, diabetic macular edema
Atchoo! Who’s making money out of flu season
CNBC
Friday, October 18, 2013 - 9:34am
tags:
Flu, Novartis, GSK, Merck, Sanofi, AstraZeneca
Bubble-icious Biotech
Forbes
Friday, October 18, 2013 - 9:33am
tags:
IPOs, biotech
Ariad Forced to Shutter Vital Study of Iclusig Due to Toxicity
TheStreet.com
Friday, October 18, 2013 - 9:32am
tags:
Iclusig, Ariad Pharmaceuticals
Amgen's 3Q report to focus on cancer drugmaker purchase, testing of its own experimental drugs
Yahoo/AP
Friday, October 18, 2013 - 9:31am
tags:
Amgen, earnings
Cleveland Clinic picks top 3 blockbuster drug candidates in the late-stage pipeline
Fierce Biotech
Thursday, October 17, 2013 - 6:18pm
tags:
Cleveland Clinic, JNJ, Pharmacyclics, Novartis, serelaxin, ibrutinib, sofosbuvir, Gilead
Could This New Drug Application Lead to a Giant Leap for MannKind?
Motley Fool
Thursday, October 17, 2013 - 6:14pm
tags:
MannKind, Afrezza, diabetes, Pfizer
Is Amarin's FDA Panel Important for Other Cardiovascular Drugmakers?
Motley Fool
Thursday, October 17, 2013 - 6:12pm
tags:
FDA, Vascepa, Amarin, AstraZeneca, Regeneron, Amgen
Stryker 3rd-quarter net profit falls due to recalls as sales rise
Reuters
Thursday, October 17, 2013 - 6:10pm
tags:
Stryker, earnings, devices
Why Express Scripts Tossed 48 Drugs Off Its Formulary: Miller Explains
Pharmalot
Thursday, October 17, 2013 - 4:03pm
tags:
Express Scripts, formulary
Amarin's Downfall? Other People's Data
Seeking Alpha
Thursday, October 17, 2013 - 3:47pm
tags:
Amarin, Vascepa
AstraZeneca, Amgen Crohn's drug runs into PhII 'logistical' snafu
Fierce Biotech
Thursday, October 17, 2013 - 10:57am
tags:
Amgen, Crohn's Disease, AMG 181, AstraZeneca
Medical products maker Baxter's profit falls on Gambro costs
Reuters
Thursday, October 17, 2013 - 10:54am
tags:
Baxter International, earnings, devices
Amarin Implosion: The Future Went from Promising to Doubtful
Yahoo/Wall St 24-7
Thursday, October 17, 2013 - 10:52am
tags:
Amarin, FDA, Vascepa
Is Eli Lilly about to start cutting its blockbuster R&D budget?
Fierce Biotech
Thursday, October 17, 2013 - 10:49am
tags:
R&D, Eli Lilly

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.